Cardiac implant developer Encore Medical disclosed the terms for its initial public offering (IPO) on Tuesday. The company plans to issue 3 million shares at $5 per share, aiming to raise $15 million. Encore Medical intends to list on the New York Stock Exchange under the ticker symbol "EMI." The company is headquartered in Eagan, Minnesota. The firm develops and manufactures ventricular septal occluders, which are implantable products delivered via catheter to repair certain heart defects, such as patent foramen ovale (PFO). The company's device has already been approved for sale in the European Union. While it has not yet received regulatory approval to market its device in the United States, the company has secured approval from the U.S. Food and Drug Administration (FDA) to conduct trials to obtain market authorization. Data shows the company generated revenue of $2 million for the 12-month period ending September 30, 2025.